INGN vs JNJ
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
INGN exhibits severe operational distress, highlighted by a critical Piotroski F-Score of 1/9, indicating a significant deterioration in financial health. While the company maintains a strong liquidity position with a Current Ratio of 3.12 and very low debt (D/E 0.09), it is unable to translate this into profitability, as evidenced by negative operating margins and stagnant revenue growth of 2%. There is a stark disconnect between the 'Strong Buy' analyst consensus and the fundamental reality of a 5-year price collapse of 88.6%. The stock currently presents as a classic value trap, trading below book value but lacking the growth catalysts necessary for a reversal.
JNJ shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
INGN vs JNJ: Head-to-Head Comparison
This page compares Inogen, Inc. (INGN) and Johnson & Johnson (JNJ) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.